arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Neurogene Inc.

NGNE
$35.69 ▲ +0.18 (+0.51%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neurogene Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $796.1M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -11.1%
FCF / Share $-1.18
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-30.93M
↓ -36.6%
FCF / Share Free cash flow per share
$-1.18
↓ -15.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Financial Health
1
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 62 quarters